ClinicalTrials.Veeva

Menu
L

Leicester Royal Infirmary | Hope Trials Facility

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

vincristine sulfate
cyclophosphamide
carboplatin
Carboplatin
cisplatin
etoposide
Cisplatin
Cyclophosphamide
doxorubicin hydrochloride
Dexamethasone

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

51 of 283 total trials

A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke (REvive)

The purpose of this study is to evaluate the efficacy and safety of redasemtide in adult participants with acute ischemic stroke (AIS).

Enrolling
Acute Ischemic Stroke
Biological: Redasemtide
Drug: Placebo

This is a Phase 3 double-blind, placebo-controlled, randomized study designed to investigate whether tafasitamab and lenalidomide as an add-on to rit...

Active, not recruiting
Marginal Zone Lymphoma
Follicular Lymphoma
Drug: tafasitamab
Drug: placebo

An open-label, single-arm, phase II, multicentre clinical trial to determine the rate of durable clinical benefit of nivolumab in patients with class...

Active, not recruiting
Colorectal Cancer
Drug: Nivolumab

Study GO43104 is a Phase III, randomized, open-label, multicenter study of lurbinectedin in combination with atezolizumab compared with atezolizumab...

Active, not recruiting
Small-Cell Lung Cancer
Drug: Atezolizumab
Drug: Lurbinectedin

The purpose of this extension study is to provide continued treatment with Roche investigational medicinal product (IMP\[s\]) monotherapy or Roche IM...

Enrolling
Cancer
Drug: Ipatasertib
Drug: Tiragolumab

This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with end...

Enrolling
Early Breast Cancer
Drug: Endocrine Therapy of Physician's Choice
Drug: Abemaciclib

The purpose of this study is to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombin...

Enrolling
Carcinoma, Non-small-Cell Lung
Drug: Lazertinib
Drug: Direct Oral Anticoagulant (DOAC)

First-in-human, open-label, sequential dose escalation and expansion study of CPI-0209 in patients with advanced solid tumors and lymphomas. CPI-0209...

Enrolling
Endometrial Cancer
Lymphoma, T-Cell
Drug: CPI-0209

This clinical trial is a Phase 2/3 study that will evaluate the efficacy and safety of etavopivat and test how well etavopivat works compared to plac...

Enrolling
Sickle Cell Disease
Drug: Placebo Tablets
Drug: Etavopivat Tablets High dose

The purpose of this study is to determine the safety, tolerability, maximum tolerated doses (MTDs) and recommended Phase 2 doses (RP2Ds) of JNJ-74856...

Active, not recruiting
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Drug: VEN
Drug: AZA

The purpose of this study is to characterize safety and to determine the putative recommended Phase 2 dose(s) (RP2D\[s\]) and optimal dosing schedule...

Active, not recruiting
Lymphoma, Non-Hodgkin
Leukemia, Lymphocytic, Chronic, B-Cell
Drug: JNJ-75348780

This study aims to examine the efficacy and safety of obexelimab in participants with Warm Autoimmune Hemolytic Anemia (wAIHA).

Active, not recruiting
Warm Autoimmune Hemolytic Anemia
Other: Placebo
Drug: Obexelimab

This study will be conducted in two parts. Part 1 will be the Dose Confirmation portion to determine recommended Phase 3 dose (RPTD) of venetoclax in...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Drug: Venetoclax
Drug: Azacitidine

The purpose of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL. Participants...

Active, not recruiting
Leukemia, B-cell
Small Lymphocytic Lymphoma
Drug: Pirtobrutinib
Drug: Ibrutinib

The goal of the study is to assess how tirzepatide impacts bodyweight and cardiovascular risk factors when used in conjunction with healthy nutrition...

Enrolling
Weight Gain
Obesity
Drug: Tirzepatide
Drug: Placebo

Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to...

Active, not recruiting
Relapsed/Refractory Multiple Myeloma
Drug: Dexamethasone
Drug: Daratumumab

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections). The purpose of th...

Enrolling
Non-Hodgkin Lymphoma
Drug: Pirtobrutinib
Drug: Ibrutinib

The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide,...

Enrolling
Relapsed or Refractory Multiple Myeloma
Drug: Pomalidomide
Drug: mezigdomide

The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinati...

Enrolling
Multiple Myeloma
Drug: Trametinib
Drug: CC-92480

The purpose of this study is to learn more about the safety and efficacy of tirzepatide compared to placebo in children or teenagers with type 2 diab...

Active, not recruiting
Type2 Diabetes
Glucose Metabolism Disorders
Drug: Placebo
Drug: Tirzepatide Dose 2

Trial sponsors

C
University College London (UCL) logo
AbbVie logo
C
U
Roche logo
I
U
E
University of Oxford logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems